Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

Filter

Feb 2024 | From Akero Therapeutics

Decreases in liver cT1 accurately reflect histological improvement induced by therapies in MASH: a multi-centre pooled cohort analysis

Nov 2023 | From Akero Therapeutics

Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist (GLP-1RA) in Patients with NASH/MASH and T2D: a Randomized, Placebo-controlled Study (Cohort D)

Oct 2023 | From Akero Therapeutics

Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebocontrolled, phase 2b trial

Jun 2023 | From Akero Therapeutics

Noninvasive tests of liver injury, inflammation and fibrosis are improved by efruxifermin and correlate with histological improvements in patients with F2-F3 NASH: secondary analysis of Ph2b HARMONY study

Jun 2023 | From Akero Therapeutics

Characterization of the Patterns of Resolution of Histopathology After Efruxifermin Treatment of Patients with NASH Fibrosis (F2/3) for 24 Weeks

Mar 2023 | From Akero Therapeutics

Efruxifermin, a long-acting, bivalent FGF21 analog, normalized noninvasive measures of liver injury, fibrosis, and metabolic health in patients with NASH and F2/F3 fibrosis over 24 weeks

Mar 2023 | From Akero Therapeutics

Efruxifermin, a bivalent Fc-FGF21 analog, demonstrated improved biophysical and pharmacological engagement with live cells compared to monovalent FGF21 analogs

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.

We are evaluating potential treatments for NASH and other serious metabolic diseases to build our pipeline.